‘Convincing’ phase 3 data needed for wet AMD gene therapy

Coverage, in order

1. 9h ago
   
   Healio indie randomized trial

   ‘Convincing’ phase 3 data needed for wet AMD gene therapy

   NEW ORLEANS — In this video from the American Academy of Ophthalmology meeting, Sharon Fekrat, MD, FACS, FASRS, highlights “exciting” gene therapy programs with phase 3 trials now underway. Fekrat, of Duke Health, detailed encouraging data on 4D-150 (4D Molecular Therapeutics), an intravitreal gene…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.